Zai Lab Ltd ZLAB:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 08/15/22 EDT
45.78UNCH (UNCH)
Volume
4,639
Close
45.78quote price arrow up+1.61 (+3.65%)
Volume
490,860
52 week range
22.51 - 152.82
Loading...
  • Open44.17
  • Day High46.40
  • Day Low43.00
  • Prev Close45.78
  • 52 Week High152.82
  • 52 Week High Date09/07/21
  • 52 Week Low22.51
  • 52 Week Low Date06/16/22

Key Stats

  • Market Cap4.414B
  • Shares Out96.41M
  • 10 Day Average Volume0.39M
  • Dividend-
  • Dividend Yield-
  • Beta1.06
  • YTD % Change-27.16

KEY STATS

  • Open44.17
  • Day High46.40
  • Day Low43.00
  • Prev Close45.78
  • 52 Week High152.82
  • 52 Week High Date09/07/21
  • 52 Week Low22.51
  • 52 Week Low Date06/16/22
  • Market Cap4.414B
  • Shares Out96.41M
  • 10 Day Average Volume0.39M
  • Dividend-
  • Dividend Yield-
  • Beta1.06
  • YTD % Change-27.16

RATIOS/PROFITABILITY

  • EPS (TTM)-5.85
  • P/E (TTM)-7.82
  • Fwd P/E (NTM)-10.21
  • EBITDA (TTM)-545.684M
  • ROE (TTM)-47.80%
  • Revenue (TTM)170.93M
  • Gross Margin (TTM)64.68%
  • Net Margin (TTM)-323.22%
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date08/21/2022(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Zai Lab Ltd

There is no recent news for this security.

Profile

MORE
Zai Lab Ltd is a holding company mainly engaged in the biopharmaceutical field. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including oncology, autoimmune and infectious diseases fields. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include Niraparib...
Du Ying Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Joshua Smiley
Chief Operating Officer
Billy Cho
Chief Financial Officer
Address
4560 Jinke Road, Bldg. 1, 4/F, Pudong
Shanghai, SHA
201210
China

Top Peers

SYMBOLLASTCHG%CHG
CYTK
Cytokinetics Inc
50.83+0.53+1.05%
GBT
Global Blood Therapeutics Inc
67.04+0.29+0.43%
DNLI
Denali Therapeutics Inc
37.61-0.50-1.31%
ITCI
Intra-Cellular Therapies Inc
52.53-1.04-1.94%
BEAM
Beam Therapeutics Inc
70.31+1.23+1.78%